Cisplatin

Open Access
Transcriptome-based Deep Learning Model for Predicting Gemcitabine and Cisplatin Chemotherapy Response in Urothelial Carcinoma: Development and External Validation
JUWON KANG, HYUN JUNG LEE, SANG-BO OH, JONG KIL NAM, TAE UN KIM, HWASEONG RYU, YONG KAN KI, JIHOON KANG, YI RANG KIM, JEONG HOON LEE, JUNJEONG CHOI, YUN JEONG HONG and KWONOH PARK

Cancer Genomics & Proteomics May 2026, 23 (3) 546-557; DOI: https://doi.org/10.21873/cgp.20589
Open Access
GULP1 as a Downstream Effector of the Estrogen Receptor-β Modulates Cisplatin Sensitivity in Bladder Cancer
TOMOYUKI TATENUMA, TAKUO MATSUKAWA, TAKURO GOTO, GUIYANG JIANG, ADHYA SHARMA, MOHAMMAD AMIN ELAHI NAJAFI, YUKI TERAMOTO and HIROSHI MIYAMOTO

Cancer Genomics & Proteomics November 2024, 21 (6) 557-565; DOI: https://doi.org/10.21873/cgp.20472
You have access
Cisplatin and Pemetrexed Have Distinctive Growth-inhibitory Effects in Monotherapy and Combination Therapy on KRAS-dependent A549 Lung Cancer Cells
MD MOHIUDDIN and KAZUO KASAHARA

Cancer Genomics & Proteomics July 2021, 18 (4) 579-590; DOI: https://doi.org/10.21873/cgp.20282
You have access
Cisplatin Activates the Growth Inhibitory Signaling Pathways by Enhancing the Production of Reactive Oxygen Species in Non-small Cell Lung Cancer Carrying an EGFR Exon 19 Deletion
MD MOHIUDDIN and KAZUO KASAHARA

Cancer Genomics & Proteomics May 2021, 18 (3 Suppl) 471-486; DOI: https://doi.org/10.21873/cgp.20273

Main menu